Internal benchmarks show that Ptarmigan-1 can run 5,000x faster than structure-based methods and screen over three billion compounds in a day.
Most screening readouts are snapshots. An endpoint measurement can obscure differences in association rate and dissociation ...
New research reveals how MRSA exploits the kidney’s hyperosmotic inner medulla to evade immune defenses, establish a persistent reservoir, and spread.
One of the strongest signals, albeit weaker than the original GWAS findings two decades ago, highlighted a novel regulatory ...
Mayo Clinic researchers have discovered that adults aged 50 years or younger with colorectal and breast cancers have distinct gut microbiome patterns compared with individuals diagnosed later in life.
AI-guided structural modeling and proteomics identified molecular glues that degrade VAV1, a potential target in blood cancers and autoimmune diseases.
Merck acquires global rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral KRAS G12D inhibitor, in a deal worth up ...
Consortium members are expected to have access to the dataset by early 2027, and there are plans to add more complex antibody ...
The findings by scientists at NYU Abu Dhabi provide new insight into how cells respond when cancer-causing genes are ...
Researchers at Washington University School of Medicine in St. Louis have developed a potential antibody-based approach to ...
Researchers at the Nano Life Science Institute at Kanazawa University in Japan say they have directly visualized how enzymes ...
The finding may make it possible to launch saRNA vaccines faster for use in gene therapy, cancer immunotherapy, and protein replacement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results